REG - AstraZeneca PLC - AZN: Full-Year 2017 Results <Origin Href="QuoteRef">AZN.L</Origin> - Part 4
02/02/2018 07:05
- Part 4: For the preceding part double click ID:nRSB7444Dc
639 (1,778)
Total comprehensive income for the period 3,507 1,628
Profit attributable to:
Owners of the Parent 3,001 3,499
Non-controlling interests (133) (93)
2,868 3,406
Total comprehensive income attributable to:
Owners of the Parent 3,640 1,722
Non-controlling interests (133) (94)
3,507 1,628
Basic earnings per $0.25 Ordinary Share $2.37 $2.77
Diluted earnings per $0.25 Ordinary Share $2.37 $2.76
Weighted average number of Ordinary Shares in issue (millions) 1,266 1,265
Diluted weighted average number of Ordinary Shares in issue (millions) 1,267 1,266
Diluted weighted average number of Ordinary Shares in issue (millions)
1,267
1,266
Condensed Consolidated Statement of Comprehensive Income
For the quarter ended 31 December 2017 $m 2016 $m
Product Sales 5,487 5,260
Externalisation Revenue 290 325
Total Revenue 5,777 5,585
Cost of sales (1,225) (1,160)
Gross profit 4,552 4,425
Distribution costs (85) (83)
Research and development expense (1,551) (1,543)
Selling, general and administrative costs (3,078) (1,386)
Other operating income and expense 848 1,120
Operating profit 686 2,533
Finance income 49 23
Finance expense (316) (362)
Share of after tax losses in associates and joint ventures (12) (11)
Profit before tax 407 2,183
Taxation 854 (366)
Profit for the period 1,261 1,817
Other comprehensive income/(loss)
Items that will not be reclassified to profit or loss
Remeasurement of the defined benefit pension liability (96) 552
Fair value movements related to own credit risk on bonds designated as fair value through profit or loss (9) -
Tax on items that will not be reclassified to profit or loss (7) (120)
(112) 432
Items that may be reclassified subsequently to profit or loss
Foreign exchange arising on consolidation 5 (360)
Foreign exchange arising on designating borrowings in net investment hedges (117) (397)
Fair value movements on cash flow hedges 85 (89)
Fair value movements on cash flow hedges transferred to profit or loss (34) 154
Fair value movements on derivatives designated in net investment hedges (9) 92
Net available for sale (losses)/gains taken to equity (47) 13
Tax on items that may be reclassified subsequently to profit or loss 92 23
(25) (564)
Other comprehensive loss for the period, net of tax (137) (132)
Total comprehensive income for the period 1,124 1,685
Profit attributable to:
Owners of the Parent 1,301 1,842
Non-controlling interests (40) (25)
1,261 1,817
Total comprehensive income attributable to:
Owners of the Parent 1,164 1,710
Non-controlling interests (40) (25)
1,124 1,685
Basic earnings per $0.25 Ordinary Share $1.03 $1.46
Diluted earnings per $0.25 Ordinary Share $1.03 $1.45
Weighted average number of Ordinary Shares in issue (millions) 1,266 1,265
Diluted weighted average number of Ordinary Shares in issue (millions) 1,267 1,266
Condensed Consolidated Statement of Financial Position
ASSETSNon-current assets
Property, plant and equipment 7,615 6,848
Goodwill 11,825 11,658
Intangible assets 26,188 27,586
Derivative financial instruments 504 343
Investments in associates and joint ventures 103 99
Other investments 933 727
Other receivables 847 901
Deferred tax assets 2,189 1,102
50,204 49,264
Current assets
Inventories 3,035 2,334
Trade and other receivables 5,009 4,573
Other investments 1,230 884
Derivative financial instruments 28 27
Income tax receivables 524 426
Cash and cash equivalents 3,324 5,018
13,150 13,262
Total assets 63,354 62,526
LIABILITIESCurrent liabilities
Interest-bearing loans and borrowings (2,247) (2,307)
Trade and other payables (11,641) (10,486)
Derivative financial instruments (24) (18)
Provisions (1,121) (1,065)
Income tax payables (1,350) (1,380)
(16,383) (15,256)
Non-current liabilities
Interest-bearing loans and borrowings (15,560) (14,501)
Derivative financial instruments (4) (117)
Deferred tax liabilities (3,995) (3,956)
Retirement benefit obligations (2,583) (2,186)
Provisions (347) (353)
Other payables (7,840) (9,488)
(30,329) (30,601)
Total liabilities (46,712) (45,857)
Net assets 16,642 16,669
EQUITY
Capital and reserves attributable to equity holders of the Company
Share capital 317 316
Share premium account 4,393 4,351
Other reserves 2,029 2,047
Retained earnings 8,221 8,140
14,960 14,854
Non-controlling interests 1,682 1,815
Total equity 16,642 16,669
Total equity
16,642
16,669
Condensed Consolidated Statement of Cash Flows
Cash flows from operating activities
Profit before tax 2,227 3,552
Finance income and expense 1,395 1,317
Share of after tax losses in associates and joint ventures 55 33
Depreciation, amortisation and impairment 3,036 2,357
(Increase)/decrease in working capital and short-term provisions (50) 926
Gains on disposal of intangible assets (1,518) (1,301)
Fair value movements on contingent consideration arising from business combinations 109 (1,158)
Non-cash and other movements (524) (492)
Cash generated from operations 4,730 5,234
Interest paid (698) (677)
Tax paid (454) (412)
Net cash inflow from operating activities 3,578 4,145
Cash flows from investing activities
Movement in short-term investments and fixed deposits (345) (166)
Purchase of property, plant and equipment (1,326) (1,446)
Disposal of property, plant and equipment 83 82
Purchase of intangible assets (294) (868)
Disposal of intangible assets 1,376 1,427
Purchase of non-current asset investments (96) (230)
Disposal of non-current asset investments 70 3
Payments to joint ventures (76) (41)
Non-contingent payments on business combinations (1,450) (2,564)
Payment of contingent consideration from business combinations (434) (293)
Interest received 164 140
Payments made by subsidiaries to non-controlling interests - (13)
Net cash outflow from investing activities (2,328) (3,969)
Net cash inflow before financing activities 1,250 176
Cash flows from financing activities
Proceeds from issue of share capital 43 47
Issue of loans 1,988 2,491
Repayment of loans (1,750) -
Dividends paid (3,519) (3,561)
Hedge contracts relating to dividend payments (20) 18
Repayment of obligations under finance leases (14) (16)
Movement in short-term borrowings 336 (303)
Net cash outflow from financing activities (2,936) (1,324)
Net decrease in cash and cash equivalents in the period (1,686) (1,148)
Cash and cash equivalents at the beginning of the period 4,924 6,051
Exchange rate effects (66) 21
Cash and cash equivalents at the end of the period 3,172 4,924
Cash and cash equivalents consists of:
Cash and cash equivalents 3,324 5,018
Overdrafts (152) (94)
3,172 4,924
4,924
Condensed Consolidated Statement of Changes in Equity
Share Share Other Retained Total attributable to owners Non- Total
capital premium reserves* earnings $m controlling equity
$m account $m $m interests $m
$m $m
At 1 Jan 2016 316 4,304 2,036 11,834 18,490 19 18,509
Profit for the period - - - 3,499 3,499 (93) 3,406
Other comprehensive income - - - (1,777) (1,777) (1) (1,778)
Transfer to other reserves - - 11 (11) - - -
Transactions with owners:
Dividends - - - (3,540) (3,540) - (3,540)
Dividends paid by subsidiary to non-controlling interest - - - - - (13) (13)
Acerta put option - - - (1,825) (1,825) - (1,825)
Changes in non-controlling interest - - - - - 1,903 1,903
Issue of Ordinary Shares - 47 - - 47 - 47
Share-based payments charge for the period - - - 241 241 - 241
Settlement of share plan awards - - - (281) (281) - (281)
Net movement - 47 11 (3,694) (3,636) 1,796 (1,840)
At 31 Dec 2016 316 4,351 2,047 8,140 14,854 1,815 16,669
Share Share Other Retained Total attributable to owners Non- Total
capital premium reserves* earnings $m controlling equity
$m account $m $m interests $m
$m $m
At 1 Jan 2017 316 4,351 2,047 8,140 14,854 1,815 16,669
Profit for the period - - - 3,001 3,001 (133) 2,868
Other comprehensive income - - - 639 639 - 639
Transfer to other reserves - - (18) 18 - - -
Transactions with owners:
Dividends - - - (3,543) (3,543) - (3,543)
Issue of Ordinary Shares 1 42 - - 43 - 43
Share-based payments charge for the period - - - 220 220 - 220
Settlement of share plan awards - - - (254) (254) - (254)
Net movement 1 42 (18) 81 106 (133) (27)
At 31 Dec 2017 317 4,393 2,029 8,221 14,960 1,682 16,642
*Other reserves include the capital redemption reserve and the merger reserve.
Notes to the Interim Financial Statements
1 BASIS OF PREPARATION AND ACCOUNTING POLICIES
The preliminary announcement for the year ended 31 December 2017 has been prepared in accordance with International
Financial Reporting Standards (IFRSs) as adopted by the European Union (EU) and as issued by the International Accounting
Standards Board (IASB).
The annual financial statements of the Group are prepared in accordance with IFRSs as adopted by the EU and as issued by
the IASB. Except as noted below, the preliminary announcement has been prepared applying the accounting policies and
presentation that were applied in the preparation of the Group's published consolidated financial statements for the year
ended 31 December 2016. From 1 January 2017 the Group early adopted the treatment of fair value changes arising from
changes in own credit risk in IFRS 9 Financial Instruments. The impact was not significant.
We have revised the balance sheet presentation of deferred tax with effect from 1 January 2017 with no impact upon net
deferred tax, the Group's net assets, the cash flow statement or the income statement. This presentation change has
resulted in us showing gross, rather than net, deferred tax assets and deferred tax liabilities of a group entity. This
change has been made as that entity has transactions that are subject to tax by two different taxation authorities and has
the effect of separately disclosing the deferred tax effects for each country. The comparative balance sheet has not been
revised for this presentational change. If the 31 December 2016 balances were presented in a comparable way the deferred
tax assets would have been $2,093m. The deferred tax liabilities would have been $4,947m.
As disclosed in our 2016 Annual Report on Page 181, the Group has entered into a number of financial derivative
transactions with commercial banks. The Group has agreements with some bank counterparties whereby the parties agree to
post cash collateral, for the benefit of the other, equivalent to the market valuation of the derivative positions above a
predetermined threshold. We have revised the balance sheet presentation of these collateral balances with effect from 1
January 2017, so that the cash collateral is included in cash and cash equivalents, with an offsetting liability presented
in current interest-bearing loans and borrowings and the movement presented in movement in short-term borrowings in the
statement of cash flows. This revision has no impact on the Group's net assets, or the income statement. The comparative
balance sheet has not been revised for this presentational change. If the 31 December 2016 balances were presented in a
comparable way the cash and cash equivalents balance would have been $5,260m. Current interest-bearing loans and borrowings
would have been $2,629m, and current investments would have been $964m.
Following clarification by the IASB Interpretations Committee in September 2017, the Group has revised its presentation of
interest and tax positions. Interest income and expense, which was previously presented in the tax charge in the income
statement, is now presented in finance income and expense and corresponding assets and liabilities, which were previously
presented as income tax receivables and payables in the balance sheet, are now presented in trade and other receivables and
trade and other payables. This revision has no impact on the Group's net assets and cash flows, or retained profit. The
Group has assessed this presentational change as not material for restatement and, therefore, the comparative income
statement and balance sheets have not been revised for this presentational change. If the 31 December 2016 balances were
presented in a comparable way, finance income and expense would have been $1,239m, the tax charge would have been $224m,
income tax payables would have been $1,287m, and trade and other payables would have been $10,579m.
Legal proceedings
The information contained in Note 5 updates the disclosures concerning legal proceedings and contingent liabilities in the
Group's Annual Report and Form 20-F Information 2016, the interim financial statements for the three months ended 31 March
2017, the interim financial statements for the three months ended 30 June 2017 and the interim financial statements for the
three months ended 30 September 2017.
Going concern
The Group has considerable financial resources available. As at 31 December 2017 the Group has $4.1bn in financial
resources (cash balances of $3.3bn and undrawn committed bank facilities of $3.0bn which are available until April 2022,
with only $2.2bn of debt due within one year). The Group's revenues are largely derived from sales of products which are
covered by patents which provide a relatively high level of resilience and predictability to cash inflows, although our
revenue is expected to continue to be significantly impacted by the expiry of patents over the medium term. In addition,
government price interventions in response to budgetary constraints are expected to continue to adversely affect revenues
in many of our mature markets. However, we anticipate new revenue streams from both recently launched medicines and
products in development, and the Group has a wide diversity of customers and suppliers across different geographic areas.
Consequently, the Directors believe that, overall, the Group is well placed to manage its business risks successfully.
On the basis of the above paragraph, the going concern basis has been adopted in these interim financial statements.
Financial information
The financial information contained in the preliminary announcement does not constitute statutory accounts of the Group for
the years ended 31 December 2017 and 2016 but is derived from those accounts. Statutory accounts for 2016 have been
delivered to the registrar of companies and those for 2017 will be delivered in due course. Those accounts have been
reported on by the Group's auditors; their report was (i) unqualified, (ii) did not include a reference to any matters to
which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement
under section 498(2) or (3) of the Companies Act 2006. The quarterly information for the three month period to 31 December
2017 and to 31 December 2016 has not been subject to audit.
2 RESTRUCTURING COSTS
Profit before tax for the year ended 31 December 2017 is stated after charging restructuring costs of $807m ($163m for the
fourth quarter of 2017). These have been charged to profit as follows:
FY 2017 FY 2016 Q4 2017 Q4 2016
$m $m $m $m
Cost of sales 181 130 53 43
Research and development expense 201 178 24 32
Selling, general and administrative costs 347 823 83 319
Other operating income and expense 78 (24) 3 -
Total 807 1,107 163 394
3 NET DEBT
The table below provides an analysis of net debt and a reconciliation of net cash flow to the movement in net debt.
The Group monitors net debt as part of its capital management policy as described in Note 26 of the Annual Report and Form
20-F Information 2016. Net debt is a non-GAAP financial measure.
At 1 Jan 2017 $m Cash Flow $m Non-cash& Other$m Exchange Movements$m At 31 Dec 2017 $m
Loans due after one year (14,495) (1,988) 1,389 (466) (15,560)
Finance leases due after one year (6) - 6 - -
Total long-term debt (14,501) (1,988) 1,395 (466) (15,560)
Current instalments of loans (1,769) 1,750 (1,378) - (1,397)
Current instalments of finance leases (87) 14 69 (1) (5)
Total current debt (1,856) 1,764 (1,309) (1) (1,402)
Other investments - current 884 345 - 1 1,230
Other investments - non-current 14 56 - - 70
Net derivative financial instruments 235 20 249 - 504
Cash and cash equivalents 5,018 (1,629) - (65) 3,324
Overdrafts (94) (57) - (1) (152)
Short-term borrowings (357) (336) - - (693)
5,700 (1,601) 249 (65) 4,283
Net debt (10,657) (1,825) 335 (532) (12,679)
Non-cash movements in the period include fair value adjustments under IAS 39.
4 FINANCIAL INSTRUMENTS
As detailed in the Group's most recent annual financial statements, our principal financial instruments consist of
derivative financial instruments, other investments, trade and other receivables, cash and cash equivalents, trade and
other payables, and interest-bearing loans and borrowings. The accounting policies for financial instruments, including
fair value measurement, can be found on pages 144 and 145 of the Company's Annual Report and Form 20-F Information 2016.
There have been no significant new or revised accounting standards applied in the year ended 31 December 2017 and there
have been no changes of significance to the categorisation or fair value hierarchy classification of our financial
instruments. During the year, we revised the balance sheet presentation of cash collateral balances held with commercial
bank counterparties, effective from 1 January 2017 (see Note 1).
Financial instruments measured at fair value include $1,230m of other investments, $1,247m of loans, and $504m of
derivatives as at 31 December 2017. The total fair value of interest-bearing loans and borrowings at 31 December 2017 which
have a carrying value of $17,807m in the Condensed Consolidated Statement of Financial Position, was $19,280m. Contingent
consideration liabilities arising on business combinations have been classified under Level 3 in the fair value hierarchy
and movements in fair value are shown below:
DiabetesAlliance2017 Other 2017 Total 2017 Total 2016
$m $m $m $m
At 1 January 4,240 1,217 5,457 6,411
Settlements (284) (150) (434) (293)
Revaluations 208 (99) 109 (1,158)
Discount unwind 313 89 402 497
Foreign exchange - - - -
At 31 December 4,477 1,057 5,534 5,457
5 LEGAL PROCEEDINGS AND CONTINGENT LIABILITIES
AstraZeneca is involved in various legal proceedings considered typical to its business, including litigation and
investigations relating to product liability, commercial disputes, infringement of intellectual property rights, the
validity of certain patents, anti-trust law and sales and marketing practices. The matters discussed below constitute the
more significant developments since publication of the disclosures concerning legal proceedings in the Company's Annual
Report and Form 20-F Information 2016, the interim financial statements for the three months ended 31 March 2017, the
interim financial statements for the three months ended 30 June 2017, and the interim financial statements for the three
months ended 30 September 2017 (the Disclosures). Unless noted otherwise below or in the Disclosures, no provisions have
been established in respect of the claims discussed below.
As discussed in the Disclosures, for the majority of claims in which AstraZeneca is involved it is not possible to make a
reasonable estimate of the expected financial effect, if any, that will result from ultimate resolution of the proceedings.
In these cases, AstraZeneca discloses information with respect only to the nature and facts of the cases but no provision
is made.
In cases that have been settled or adjudicated, or where quantifiable fines and penalties have been assessed and which are
not subject to appeal, or where a loss is probable and we are able to make a reasonable estimate of the loss, we record the
loss absorbed or make a provision for our best estimate of the expected loss.
The position could change over time and the estimates that we have made and upon which we have relied in calculating these
provisions are inherently imprecise. There can, therefore, be no assurance that any losses that result from the outcome of
any legal proceedings will not exceed the amount of the provisions that have been booked in the accounts. The major factors
causing this uncertainty are described more fully in the Disclosures and herein.
AstraZeneca has full confidence in, and will vigorously defend and enforce, its intellectual property.
Matters disclosed in respect of the fourth quarter of 2017 and to 2 February 2018.
Patent litigation
Faslodex (fulvestrant)
US patent proceedings
As previously disclosed, in March and October 2017, AstraZeneca received Paragraph IV notices regarding NDAs submitted
pursuant to 21 U.S.C. § 355(b)(2) by Teva Pharmaceuticals USA, Inc. (Teva) and Fresenius Kabi USA LLC (Fresenius),
respectively, relating to four FDA Orange Book-listed patents. As previously disclosed, in April 2017, AstraZeneca filed a
lawsuit against Teva in the US District Court for the District of New Jersey (the District Court). In December 2017,
AstraZeneca filed lawsuits against Fresenius in both the District Court and the US District Court for the District of
Delaware. In January 2018, AstraZeneca settled the lawsuits against both Teva and Fresenius and consent judgements have
been entered, ending the lawsuits.
Calquence (acalabrutinib)
US patent proceedings
As previously disclosed, in November 2017, Pharmacyclics LLC filed a complaint in the US District Court for the District of
Delaware against Acerta Pharma B.V., Acerta Pharma LLC, and AstraZeneca (collectively, AstraZeneca) alleging that Calquence
infringes certain claims of US Patent Nos. 9,079,908; 9,139,591; and 9,556,182. In January 2018, AstraZeneca filed an
answer to the complaint alleging, inter alia, that the asserted patents are invalid and not infringed.
Byetta (exenatide)
US patent proceedings
As previously disclosed, in December 2015, AstraZeneca filed a patent infringement lawsuit in response to a Paragraph IV
notice from Amneal Pharmaceuticals LLC (Amneal) relating to patents listed in the FDA Orange Book with reference to Byetta.
In October 2017, AstraZeneca settled the patent litigation against Amneal. A consent judgment was entered in the US
District Court for the District of Delaware which will enjoin Amneal from launching its proposed exenatide Abbreviated New
Drug Application product until April 2018, subject to regulatory approval.
Patent proceedings outside the US
In December 2017, the Barcelona Court of Appeals lifted a nationwide interim injunction that AstraZeneca had previously
obtained against Sandoz Farmacéutica, S. A. (Sandoz) after Sandoz received regulatory approval to market generic versions
of Faslodex in Spain.
Tagrisso (osimertinib)
Patent proceedings outside the US
In Europe, in October 2016, Stada Arzneimittel AG filed an opposition to the grant of European Patent No. 2,736,895 (the
'895 patent). The European Patent Office Opposition Hearing took place in January 2018 and the '895 patent was upheld.
Product liability litigation
Byetta/Bydureon(exenatide)
As previously disclosed, in the US, Amylin Pharmaceuticals, LLC, a wholly owned subsidiary of AstraZeneca, and/or
AstraZeneca are among multiple defendants in various lawsuits filed in federal and state courts involving claims of
physical injury from treatment with Byetta and/or Bydureon. The lawsuits allege several types of injuries including
pancreatitis, pancreatic cancer, thyroid cancer, and kidney cancer. A multi-district litigation has been established in the
US District Court for the Southern District of California (the District Court) in regard to the alleged pancreatic cancer
cases in federal courts. Further, a coordinated proceeding has been established in Los Angeles, California in regard to the
various lawsuits in California state courts.
In November 2015, the District Court granted the defendants' motion for summary judgment and dismissed all claims alleging
pancreatic cancer that accrued prior to 11 September 2015. In November 2017, the US Court of Appeals for the Ninth Circuit
annulled the District Court's order and remanded for further discovery. The appeal of a similar motion, which was granted
in favour of defendants in the California state coordinated proceeding in May 2016, remains pending
Crestor (rosuvastatin calcium)
As previously disclosed, in the US, AstraZeneca was defending a number of lawsuits alleging multiple types of injuries
caused by the use of Crestor, including diabetes mellitus, various cardiac injuries, rhabdomyolysis, and/or liver and
kidney injuries. AstraZeneca has resolved all active claims with regard to this matter.
Seroquel (quetiapine fumarate)
In November 2017, AstraZeneca was named as one of several defendants in a lawsuit filed in Missouri involving one plaintiff
alleging, among other things, wrongful death from treatment with Seroquel.
Commercial litigation
Array BioPharma
In December 2017, AstraZeneca was served with a complaint filed in New York State court by Array BioPharma, Inc. (Array)
that alleged, among other things, breaches of contractual obligations relating to a 2003 collaboration agreement between
AstraZeneca and Array.
6 product analysis - FY 2017
The table below provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting
year-on-year growth.
World Emerging Markets US Europe Established ROW
FY 2017$m Actual% CER% FY 2017$m Actual% CER FY 2017$m Actual% FY 2017$m Actual% CER% FY 2017$m Actual% CER%
%
Oncology
Tagrisso 955 126 126 135 n/m n/m 405 59 187 146 142 228 175 183
Iressa 528 3 3 251 8 8 39 70 112 (7) (8) 126 (8) (6)
Lynparza 297 36 35 18 n/m n/m 141 11 130 60 58 8 n/m n/m
Imfinzi 19 n/m n/m - - - 19 n/m - - - - - -
Calquence 3 n/m n/m - - - 3 n/m - - - - - -
Legacy:
Faslodex 941 13 13 115 20 18 492 12 256 12 11 78 15 18
Zoladex 735 (10) (9) 353 (1) (1) 15 (57) 141 (10) (8) 226 (16) (15)
Casodex 215 (13) (11) 108 1 4 (1) n/m 22 (19) (19) 86 (23) (21)
Arimidex 217 (6) (4) 118 7 10 7 (50) 34 (8) (8) 58 (18) (15)
Others 114 10 13 28 12 16 - - 3 (63) (63) 83 17 20
Total Oncology 4,024 19 19 1,126 19 20 1,120 25 885 21 20 893 10 12
CVMD
Brilinta 1,079 29 29 224 19 21 509 46 295 14 13 51 16 11
Farxiga 1,074 29 28 232 74 73 489 7 242 29 28 111 91 90
Onglyza 611 (15) (16) 130 (8) (10) 320 (15) 104 (21) (21) 57 (19) (20)
Bydureon 574 (1) (1) 9 125 75 458 (1) 88 (12) (11) 19 73 73
Byetta 176 (31) (30) 12 (50) (50) 114 (30) 34 (24) (22) 16 (24) (24)
Symlin 48 20 20 - - - 48 20 - - - - - -
Qtern 5 n/m n/m 1 n/m n/m 4 n/m - - - - - -
Legacy:
Crestor 2,365 (30) (30) 784 9 11 373 (70) 666 (23) (23) 542 (8) (6)
Seloken/Toprol-XL 695 (6) (4) 593 11 12 37 (61) 52 (42) (41) 13 (19) (19)
Atacand 300 (5) (3) 178 10 12 19 (47) 86 (11) (11) 17 (15) (15)
Others 339 (15) (13) 204 (11) (7) - - 92 (23) (24) 43 (14) (12)
Total CVMD 7,266 (10) (10) 2,367 11 12 2,371 (26) 1,659 (12) (13) 869 (1) -
Respiratory
Symbicort 2,803 (6) (6) 439 9 10 1,099 (12) 819 (10) (10) 446 2 2
Pulmicort 1,176 11 12 840 20 23 156 (10) 92 (7) (8) 88 (2) (1)
Daliresp/Daxas 198 29 28 4 - - 167 25 26 73 73 1 - -
Tudorza/Eklira 150 (12) (12) 2 n/m n/m 66 (14) 73 (12) (11) 9 - -
Duaklir 79 25 25 - n/m n/m - - 77 24 24 2 - -
Bevespi 16 n/m n/m - - - 16 n/m - - - - - -
Others 284 (10) (9) 103 (25) (24) 5 (44) 129 10 10 47 (6) (8)
Total Respiratory 4,706 (1) (1) 1,388 12 13 1,509 (8) 1,216 (5) (5) 593 1 1
Other
Nexium 1,952 (4) (3) 684 (1) 2 499 (10) 248 (1) (3) 521 (3) (1)
Synagis 687 1 1 - - - 317 (2) 370 5 5 - - -
Losec/Prilosec 271 (2) (1) 140 9 10 11 10 77 (7) (7) 43 (22) (20)
Seroquel XR 332 (55) (55) 62 (10) (12) 175 (66) 78 (42) (42) 17 - -
Movantik/Moventig 122 34 34 - n/m n/m 120 33 2 n/m n/m - - -
FluMist/Fluenz 78 (25) (28) (1) n/m n/m - (100) 76 17 12 3 (50) (50)
Others 714 (38) (38) 383 (34) (32) 47 (55) 142 (47) (49) 142 (28) (28)
Total Other 4,156 (18) (17) 1,268 (14) (12) 1,169 (28) 993 (14) (15) 726 (11) (9)
TOTAL PRODUCT SALES 20,152 (5) (5) 6,149 6 8 6,169 (16) 4,753 (6) (7) 3,081 - 1
7 product analysis - Q4 2017
The table below provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting
year-on-year growth.
World Emerging Markets US Europe Established ROW
Q4 2017$m Actual% CER% Q4 2017$m Actual% CER Q4 2017$m Actual% Q4 2017$m Actual% CER% Q4 2017$m Actual% CER%
%
Oncology
Tagrisso 304 107 105 50 n/m n/m 128 73 63 133 115 63 58 68
Iressa 130 10 8 51 11 7 12 71 32 10 3 35 (3) 3
Lynparza 100 61 58 7 n/m n/m 54 74 36 44 32 3 n/m n/m
Imfinzi 18 n/m n/m - - - 18 n/m - - - - - -
Calquence 3 n/m n/m - - - 3 n/m - - - - - -
Legacy:
Faslodex 238 7 5 27 4 4 124 6 62 5 (3) 25 25 30
Zoladex 187 (20) (21) 93 (21) (22) (1) n/m 37 (5) (10) 58 (18) (14)
Casodex 54 (10) (8) 30 20 20 (2) n/m 5 (38) (38) 21 (22) (19)
Arimidex 57 - (2) 33 22 22 2 - 8 (20) (20) 14 (22) (17)
Others 29 - 3 7 40 40 - - (1) - - 23 15 20
Total Oncology 1,120 20 19 298 17 15 338 41 242 20 12 242 3 9
CVMD
Brilinta 299 27 24 49 (8) (8) 154 47 82 24 15 14 17 8
Farxiga 332 39 37 72 76 76 150 15 71 39 31 39 129 124
Onglyza 180 21 19 37 16 13 103 43 26 (13) (17) 14 (7) (13)
Bydureon 147 4 2 4 n/m n/m 115 1 23 (8) (8) 5 67 67
Byetta 48 (13) (13) 3 (40) (40) 33 (11) 8 - - 4 (20) (20)
Symlin 13 - - - - - 13 - - - - - - -
Qtern 5 n/m n/m 1 n/m n/m 4 n/m - - - - - -
Legacy:
Crestor 594 (6) (7) 207 14 14 127 34 152 (27) (32) 108 (26) (23)
Seloken/Toprol-XL 168 (6) (7) 156 16 14 3 (79) 4 (83) (83) 5 (17) (17)
Atacand 73 (10) (10) 43 (4) (4) 2 (75) 23 - - 5 - -
Others 80 (8) (10) 47 4 - (2) n/m 23 (23) (27) 12 - -
Total CVMD 1,939 7 6 619 15 14 702 19 412 (11) (16) 206 (7) (5)
- More to follow, for following part double click ID:nRSB7444DeRecent news on AstraZeneca
See all newsRCS - LHH - LHH, EZRA's AI Leadership Transformation Program
AnnouncementREG - AstraZeneca PLC - Baxdrostat met primary endpoint in Bax24 Ph3 trial
AnnouncementREG - AstraZeneca PLC - Datroway improved OS and PFS in TROPION-Breast02
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Enhertu improved IDFS in early BC in DB-05
Announcement